Vaxart, Inc. Files 8-K: Other Events & Exhibits
Ticker: VXRT · Form: 8-K · Filed: Dec 5, 2024 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, exhibits
TL;DR
Vaxart filed an 8-K on Dec 5 for events on Dec 2, covering 'Other Events' and exhibits.
AI Summary
Vaxart, Inc. filed an 8-K on December 5, 2024, reporting an event that occurred on December 2, 2024. The filing pertains to "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS, is incorporated in Delaware and headquartered in South San Francisco, California.
Why It Matters
This 8-K filing indicates Vaxart is disclosing material information or submitting required exhibits, which could impact investor understanding of the company's current status or financial reporting.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of events and exhibits, not indicating immediate financial distress or significant operational changes.
Key Numbers
- 001-35285 — SEC File Number (Identifies Vaxart's filing with the SEC)
- 59-1212264 — IRS Employer Identification No. (Tax identification for Vaxart)
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- Aviragen Therapeutics, Inc. (company) — Former Company Name
- Biota Pharmaceuticals, Inc. (company) — Former Company Name
- NABI BIOPHARMACEUTICALS (company) — Former Company Name
- December 2, 2024 (date) — Earliest event reported
- December 5, 2024 (date) — Filing Date
FAQ
What specific 'Other Events' are being reported by Vaxart, Inc. in this 8-K filing?
The filing does not detail the specific 'Other Events' beyond listing the item category.
What financial statements or exhibits are included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item information category but does not specify which ones are included.
When was Vaxart, Inc. previously known by other names?
Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc. (effective 20160413), Biota Pharmaceuticals, Inc. (effective 20121113), and NABI BIOPHARMACEUTICALS (effective 20100719).
What is Vaxart, Inc.'s principal executive office address?
Vaxart, Inc.'s principal executive offices are located at 170 Harbor Way, Suite 300, South San Francisco, California, 94080.
What is the SIC code for Vaxart, Inc.?
The Standard Industrial Classification (SIC) code for Vaxart, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-12-04 17:52:24
Key Financial Figures
- $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
Filing Documents
- vxrt20241204_8k.htm (8-K) — 26KB
- ex_754217.htm (EX-99.1) — 13KB
- 0001437749-24-036730.txt ( ) — 173KB
- vxrt-20241202.xsd (EX-101.SCH) — 3KB
- vxrt-20241202_def.xml (EX-101.DEF) — 11KB
- vxrt-20241202_lab.xml (EX-101.LAB) — 15KB
- vxrt-20241202_pre.xml (EX-101.PRE) — 11KB
- vxrt20241204_8k_htm.xml (XML) — 3KB
01
Item 8.01. Other Events. On December 2, 2024, Vaxart, Inc. (the "Company") issued a press release (the "Press Release") announcing completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating the Company's oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator (the "Trial"). A copy of the Press Release is attached to this Current Report on Form 8-K as Exhibit 99.1 and, other than the quotes by Dr. James F. Cummings, is incorporated herein by reference. As an update to matters discussed in the Press Release, the sentinel cohort of the Trial comprised of 404 participants randomized, with at least 200 receiving the Company's COVID-19 vaccine candidate and approximately 200 receiving an approved mRNA vaccine comparator. The last dose administered to complete enrollment was November 26, 2024.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated December 2, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VAXART, INC. Dated: December 4, 2024 By: /s/ Steven Lo Steven Lo President and Chief Executive Officer